Med-Life Discoveries LP
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 27, 2027The maintenance fee for Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof (US 9,169,280) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
- 2 fees due Nov 10 to 19, 2027 · next Nov 10
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,993,623 | Method for Lowering Cholesterol In force · Medium confidence | In force | Medium confidence | |
| US 9,517,222 | Method for the treatment of senile dementia of the Alzheimer's type In force · USPTO record | In force | USPTO record | |
| US 10,123,989 | Method of lowering cholesterol In force · USPTO record | In force | USPTO record | |
| US 10,697,969 | Methods for diagnosing a colorectal cancer (CRC) health state or change in CRC health state, or for diagnosing risk of developing CRC or the presence of CRC in a subject In force · USPTO record | In force | USPTO record | |
| US 8,304,246 | Methods for the diagnosis of dementia and other neurological disorders In force · USPTO record | In force | USPTO record | |
| US 10,302,624 | Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging In force · Medium confidence | In force | Medium confidence | |
| US 10,656,155 | Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis In force · High confidence | In force | High confidence | |
| US 9,034,923 | Methods for the Treatment of Senile Dementia of the Alzheimer's Type In force · High confidence | In force | High confidence | |
| US 9,169,280 | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof In force · USPTO record | In force | USPTO record | |
| US 9,334,235 | Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 11: 6 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 no status recorded